TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26171754
Drug: Regular monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular monthly home visits (no video consultation)
Study: 22304676
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment groups (post-treatment and 1-month follow-up)
Study: 22304676
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment groups (1-month follow-up)
Study: 12365197
Drug: Diphenhydramine 120
Normalized name: pseudoephed/diphenhydramine 120 mg-100 mg ORAL TABLET, EXTENDED RELEASE 12 HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 120 mg
Study: 10421239
Drug: Pramlintide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide (30 microg four times daily)
Study: 2264198
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with the BCG vaccine (Group 2)
Study: 2264198
Drug: Levamisole for
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole for immunotherapy (Group 3)
Study: 2264198
Drug: Combined method:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined method: BCG vaccine, placental suspension, and cyclophosphamide (Group 4)
Study: 28869573
Drug: LEU (L-leucine)
Normalized name: Leu
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LEU (L-leucine)
Study: 21365629
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Lonafarnib (LNF) and Docetaxel (DTX)
Study: 17522596
Drug: Rivastigmine transdermal
Normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine transdermal patch (5-20 cm2)
Study: 17522596
Drug: Rivastigmine capsules
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine capsules (1.5-6 mg Q12H, i.e., 3-12 mg/day)
Study: 16440148
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) administered intravenously during the operation
Study: 10891820
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (1 mg/m²/d) for 24 months
Study: 31570179
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg L-DOPA
Study: 26088460
Drug: Pre-RT temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pre-RT temozolomide followed by concurrent temozolomide and radiotherapy (RT)
Study: 26088460
Drug: Pre-RT temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pre-RT temozolomide followed by concurrent temozolomide and RT
Study: 26088460
Drug: Pre-RT temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pre-RT temozolomide followed by concurrent temozolomide and RT in codeleted patients
Study: 26088460
Drug: Pre-RT temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pre-RT temozolomide followed by concurrent temozolomide and RT in non-codeleted patients
Study: 20226502
Drug: Weekly irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly irinotecan (Iri) 35 mg/m(2) and cisplatin (CP) 20 mg/m(2) with 45‐Gy pelvic irradiation
Study: 19213341
Drug: Integrative medical
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrative medical treatment plus prednisone
Study: 16860509
Drug: Warfarin plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin plasma concentration monitoring
Study: 16860509
Drug: Warfarin dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin dosage and concentration correlation with INR
Study: 6314747
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 micrograms/kg bolus followed by 5 micrograms/kg/h infusion)
Study: 29940217
Drug: BNX-RDT 11.4/2.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNX-RDT 11.4/2.9 mg
Study: 29940217
Drug: BNX-RDT 2.9/0.71
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNX-RDT 2.9/0.71 mg
Study: 21962726
Drug: Buprenorphine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine treatment (BT)
Study: 1553897
Drug: Regimen A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A: metoclopramide [2 mg/kg x 4 i.v.] + methylprednisolone (250 mg x 2 i.v.) + diphenhydramine (50 mg x 2 i.v.)
Study: 1553897
Drug: Regimen B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B: metoclopramide (3 mg/kg x 2 i.v.) + dexamethasone (20 mg i.v.) + diphenhydramine (50 mg i.v.)
Study: 18312768
Drug: Combined simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined simvastatin and ezetimibe treatment
Study: 20501862
Drug: Isotretinoin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin (30 mg/d for 3 years)
Study: 16538734
Drug: Iodized salt
Normalized name: calcium iodized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodized salt with iodine concentration of 6 +/- 2 mg/kg
Study: 16538734
Drug: Iodized salt
Normalized name: calcium iodized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodized salt with iodine concentration of 15 +/- 2 mg/kg
Study: 16538734
Drug: Iodized salt
Normalized name: calcium iodized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodized salt with iodine concentration of 24 +/- 2 mg/kg
Study: 16538734
Drug: Iodized salt
Normalized name: calcium iodized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodized salt with iodine concentration of 34 +/- 2 mg/kg
Study: 12434280
Drug: Cisplatin/epinephrine gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin/epinephrine gel
Study: 3046638
Drug: Interferon alfa-n1
Normalized name: interferon alfa-n1
DrugBank: Interferon alfa-n1 (DB00011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa-n1 (Wellferon) intramuscularly at a dosage of 5 megaunits per square meter daily for 28 days and then thrice weekly for five months
Study: 30526678
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg (TNFi-naïve)
Study: 30526678
Drug: Secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg (TNFi-naïve)
Study: 30526678
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg (TNFi-experienced)
Study: 30526678
Drug: Secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg (TNFi-experienced)
Study: 28356129
Drug: 6 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g/d probiotic
Study: 28356129
Drug: 6 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g/d synbiotic
Study: 20587582
Drug: Persistent TSH-suppressive
Normalized name: TSH-releasing hormone
DrugBank: Protirelin (DB09421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Persistent TSH-suppressive l-T4 substitution (low-TSH group)
Study: 19431244
Drug: Cortexin, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortexin, 20 mg daily for 10 days
Study: 19431244
Drug: Placebo, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 20 mg daily for 10 days
Study: 31674202
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement containing cranberry, D-mannose and anti-inflammatory molecules, taken twice a day for 2 weeks starting from surgery
Study: 20694783
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicines administered according to syndrome typing for oral intake and external washing
Study: 20694783
Drug: Glucosamine hydrochloride
Normalized name: Glucosamine Hydrochloride
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine hydrochloride and Celecoxib, combined with intra-articular injection of sodium hyaluronate and peri-articular pain spot blocking with Triamcinolone Acetonaide Acetate injection
Study: 12859160
Drug: Ramipril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (5 mg daily)
Study: 1681917
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g plus metronidazole 1.5 g once daily (n = 94)
Study: 1681917
Drug: Ampicillin 2
Normalized name: ampicillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 2 g plus netilmicin 150 mg twice daily plus metronidazole 1.5 g once daily (n = 96)
Study: 7023519
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 0.02 mg kg‐1
Study: 7023519
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 0.2 mg kg‐1
Study: 24637941
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg t.i.d. sorafenib
Study: 24637941
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg b.i.d. sorafenib
Study: 18094220
Drug: darunavir/ritonavir 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/ritonavir 400/100 mg bid
Study: 18094220
Drug: darunavir/ritonavir 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/ritonavir 400/100 mg bid plus clarithromycin 500 mg bid
Study: 16801665
Drug: Analogous therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analogous therapy in a patient with non‐CNS lymphoma
Study: 8624887
Drug: Sublingual nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual nifedipine 5 mg, repeated after 15 minutes if DBP > 120 mmHg
Study: 8624887
Drug: Intravenous hydrallazine
Normalized name: Hydrallazine
DrugBank: Hydralazine (DB01275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous hydrallazine 5 mg, repeated after 15 minutes if DBP > 120 mmHg
Study: 1419549
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg cephradine 12-hourly for seven days
Study: 1419549
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg cefuroxime axetil 12-hourly for seven days
Study: 3973648
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) alone, 600 mg/m2 IV once weekly
Study: 3973648
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) plus radiation therapy, 4,000 rad, with adjuvant 5-FU, 600 mg/m2 IV for the first three days of radiotherapy, then maintenance 5-FU, 600 mg/m2 weekly
Study: 3973648
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) plus radiation therapy
Study: 28647736
Drug: 10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg of vitamin D3 supplementation daily
Study: 28647736
Drug: 30 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 µg of vitamin D3 supplementation daily
Study: 28647736
Drug: Both 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both 10 µg and 30 µg of vitamin D3 supplementation
Study: 22013143
Drug: PGF2α (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGF2α (3.5 µg/kg/min over 20 min)
Study: 19485589
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) with minimal parent involvement
Study: 19485589
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) with active parent involvement
Study: 1552888
Drug: Cefotiam (CTM-L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotiam (CTM-L group)
Study: 3553480
Drug: 1500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg/day elemental calcium for 4 weeks
Study: 24899709
Drug: Resveratrol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (200 mg/d)
Study: 22939758
Drug: High-dose grass
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose grass pollen SLIT
Study: 18337059
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (GT) 2 g of leaves in 200 mL of water, three times per day for 7 days
Study: 10926708
Drug: Oil-containing lotion
Normalized name: fish oil (containing omega-3 acids)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oil-containing lotion
Study: 18821119
Drug: Control lotion
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control lotion
Study: 8828530
Drug: Montelukast (MK-0476),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (MK-0476), 200 mg, three times daily for 10 1/3 days
Study: 6377525
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl 100 micrograms in 8 ml normal saline
Study: 6377525
Drug: Pethidine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine 1.5 mg/kg 4-6-hourly as required
Study: 29024718
Drug: Intraoperative incision
Normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative incision site injection
Study: 22456780
Drug: MEB complexed
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEB complexed with chitin nano-crystals (topical emulsion and oral hard capsules)
Study: 17885011
Drug: Cava (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cava (30 g ethanol/d for 28 days)
Study: 15213052
Drug: Gin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gin (30 g ethanol/d for 28 days)
Study: 15831802
Drug: Glu+Caf (48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glu+Caf (48 g/h + 5 mg x kg(‐1) x h(‐1))
Study: 15831802
Drug: Glu (48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glu (48 g/h)
Study: 7322717
Drug: Phenobarbital (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (daily for a mean of 35 months)
Study: 28231822
Drug: Cilostazol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (50 mg) twice per day as an add-on therapy combined with AChEIs
Study: 21068025
Drug: Escalated dose
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated dose weekly paclitaxel (80 mg/m² initially followed by 100 and 120 mg/m² unless severe toxicity is observed)
Study: 21068025
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose weekly paclitaxel (80 mg/m²)
Study: 17537155
Drug: Stress SPECT
Normalized name: spelt seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress SPECT with a low dose of TcTF (296 MBq)
Study: 14966079
Drug: Prescription
Normalized name: Rx Prescription Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription
Study: 11452245
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg oral clarithromycin twice daily for 4 days
Study: 11452245
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg oral clarithromycin
Study: 2915441
Drug: Intravenous prochlorperazine
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous prochlorperazine edisylate (10 mg)
Study: 2915441
Drug: Placebo (2-mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2-mL intravenous injection of sterile saline solution)
Study: 1107772
Drug: Zinc sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulphate (220 mg, three times a day for three weeks)
Study: 9626923
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg itraconazole for 7 days
Study: 21609915
Drug: Vasoactive agents
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive agents (Control)
Study: 15900367
Drug: Human menopausal
Normalized name: Human menopausal gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human menopausal gonadotropin (HMG) at a dose rate of 150 IU/day from day 3 of the cycle
Study: 15900367
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone (GnRH) agonist at a dose rate of 800 microg/day by nasal spray or 500 microg/day subcutaneously in the mid-luteal phase, followed by standard HMG dose after pituitary down regulation
Study: 15900367
Drug: Clomiphene at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene at a dose rate of 100 mg/day from day 3 and HMG from day 6
Study: 9066739
Drug: Excision plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excision plus isolated hyperthermic limb perfusion (IHLP) using melphalan at 2 mg/kg body weight (n = 16)
Study: 8350327
Drug: Intramuscular (im)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (im) gold plus 3 im injections of 120 mg methylprednisolone acetate
Study: 8350327
Drug: Intramuscular (im)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (im) gold plus placebo
Study: 3088664
Drug: Fluvoxamine 50
Normalized name: fluvoxamine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 50 mg twice a day
Study: 3088664
Drug: Mianserin 20
Normalized name: mianserin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin 20 mg twice a day
Study: 27315415
Drug: Problem solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem solving program delivered by physical and occupational therapy practitioners, including a structured interview and an education and resource packet.
Study: 23219490
Drug: Pay Attention!
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pay Attention! intervention (16 bi-weekly sessions)
Study: 20861424
Drug: Bupivacaine 5
Normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 5 mg/mL at 2 mL/h for 24 hours
Study: 20861424
Drug: Saline at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline at 2 mL/h for 24 hours
Study: 16372192
Drug: Local intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Local intra-arterial fibrinolysis (maximum of 50 mg rtPA injected into the ophthalmic artery)
Study: 16372192
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (bulbus massage, topical beta-blocker, acetazolamide, acetylsalicylic acid, heparin, isovolemic hemodilution)
Study: 10899723
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg clarithromycin (CLA)
Study: 10899723
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg clarithromycin (CLA)
Study: 10899723
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg clarithromycin (CLA)
Study: 10899723
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg clarithromycin (CLA)
Study: 8646825
Drug: Talinolol oral
Normalized name: talinolol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talinolol oral bioavailability.
Study: 30030269
Drug: FR +
Normalized name: sodium polystyrene sulfonate
DrugBank: Tolevamer (DB01344)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FR + L (fludarabine plus rituximab plus lenalidomide consolidation)
Study: 22201185
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with tidal volume (VT) of 8 or 6 ml kg(‐1) for TLV and OLV, respectively.
Study: 10877166
Drug: 2-day cefixime
Normalized name: (-)-cefixim
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-day cefixime (8 mg/kg/day given once daily followed by 3 days of placebo)
Study: 8415813
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose prostaglandin E1 (PGE1) infusion (0.02 microgram kg‐1 min‐1)
Study: 3534859
Drug: Captopril (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (12.5 to 50 mg b.i.d.)
Study: 3534859
Drug: Increasing doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing doses of frusemide (25 to 100 mg o.d.)
Study: 23477160
Drug: Compound Xiatianwu
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Xiatianwu combined with methotrexate (MTX)
Study: 23477160
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Compound Xiatianwu + MTX and MTX)
Study: 19930776
Drug: Daily mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily mometasone furoate nasal spray for six weeks
Study: 19930776
Drug: Self-adjusted regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-adjusted regimen of mometasone furoate nasal spray (daily for one week, every alternate day for one week, then self-adjusted for four weeks)
Study: 19930776
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (daily and self-adjusted)
Study: 28639987
Drug: Antithrombotic therapies
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapies
Study: 8627643
Drug: Bolus 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bolus 5-FU at 500 mg/m2 for 5 days followed in 2 weeks by weekly bolus 5-FU at 600 mg/m2 (Treatment A)
Study: 8627643
Drug: 5-FU at
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU at 300 mg/m2 per day by continuous infusion (Treatment C)